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The hormonal derivative of vitamin D, 1,25-dihydroxyvitamin D
(1,25[OH]2D) or calcitriol, has been implicated in many physiologic processes
beyond calcium and phosphorus homeostasis, and likely plays a role in
several chronic disease states, in particular, cardiovascular disease.
Experimental data suggest that 1,25(OH)2D affects cardiac muscle directly,
controls parathyroid hormone secretion, regulates the renin-angiotensin-
aldosterone system, and modulates the immune system. Because of these
biologic effects, vitamin D deficiency has been associated with hypertension,
several types of vascular diseases, and heart failure. We conducted a
MEDLINE search of the English-language literature (1950–2008) to identify
studies that examined these relationships; additional citations were obtained
from the articles retrieved from the literature search. Treatment with vitamin
D lowered blood pressure in patients with hypertension and modified the
cytokine profile in patients with heart failure. Measurement of serum 25-
hydroxyvitamin D concentration usually provides the best assessment of an
individual’s vitamin D status. Serum levels below 20 ng/ml represent vitamin
D deficiency, and levels above 30 ng/ml are considered optimal. Although the
observational data linking vitamin D status to cardiovascular disease appear
robust, vitamin D supplementation is not recommended as routine treatment
for heart disease until definitive prospective, randomized trials can be carried
out to assess its effects. However, such supplementation is often appropriate
for other reasons and may be beneficial to cardiovascular health in certain
patients.
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Vitamin D is a fat-soluble vitamin, and in
conjunction with parathyroid hormone, its
hormonal derivative 1,25-dihydroxyvitamin D
(1,25[OH]2D or calcitriol) is largely responsible
for the regulation of calcium and phosphorus
homeostasis. The best known pathologic
conditions associated with vitamin D deficiency
affect bone health. Severe vitamin D deficiency
can result in hypocalcemia and hypophos-
phatemia, leading to rickets and osteomalacia,
conditions characterized by inadequate bone
mineralization.1 To maintain adequate stores of
this essential nutrient, humans obtain vitamin D
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by three routes: sunlight exposure, dietary
intake, and pharmaceutical supplementation.
Vitamin D obtained from sunlight exposure is the
result of the conversion of 7-dehydrocholesterol
in the skin to vitamin D3 through solar ultra-
violet B radiation.2 Dietary and pharmaceutical
sources of vitamin D are available as either
vitamin D2 (ergocalciferol), mainly derived from
plant sources, or vitamin D3 (cholecalciferol),
primarily from animal sources. Vitamin D
obtained from any source is converted
predominantly in the liver to 25-hydroxyvitamin
D (25[OH]D).3 With relatively low biologic
activity, 25(OH)D is the major circulating form of
vitamin D in the body and is representative of
total vitamin D stores.2 The final activating step
occurs primarily in the kidney to produce
1,25(OH)2D, the biologically active form of
vitamin D.2 The physiologic effects of vitamin D
are mediated by the interaction of 1,25(OH)2D
with the vitamin D receptor (Figure 1).2, 4, 5
Although the circulating 1,25(OH)2D level
regulates calcium absorption and bone
homeostasis, it appears that local conversion of
25(OH)D to 1,25(OH)2D is important for
autocrine and paracrine signaling in many
tissues.6
Whereas most experts agree that the circulating
level of 25(OH)D represents the total vitamin D
status of an individual, what constitutes the
optimum level of this vitamin remains
controversial. Despite this debate, many
authorities currently define vitamin D deficiency
as a 25(OH)D level less than 20 ng/ml.2, 6, 7 More
recently, some have defined 25(OH)D levels
between 20 and 30 ng/ml as a relative
insufficiency in vitamin D, whereas levels over 30
ng/ml are thought to represent sufficient vitamin
D stores.2, 8, 9 The therapeutic index of vitamin D,
while broad, can be exceeded. Vitamin D
intoxication can be seen when 25(OH)D levels
exceed 150 ng/ml and can result in severe
hypercalcemia, hyperphosphatemia, and
ultimately, renal impairment (Table 1).2, 6, 7
Due to the fortification of numerous food
products with vitamin D, the prevalence of
rickets has been greatly reduced. However,
minor deficiencies are often seen, and it is
estimated that 1 billion people worldwide have
either vitamin D deficiency or relative
insufficiency.2 Age, season in which the vitamin
D status is assessed, end-organ function, and
several other factors all contribute to a person’s
vitamin D status. Risk factors for vitamin D
deficiency include the following2, 5, 10, 11:
• Inadequate sunlight exposure
• Dark skin tone
• Advanced age
• Being institutionalized
• Decreased dietary intake of vitamin D
• Living in northern latitudes
• Malabsorption syndromes
• Drugs that accelerate metabolism of
1,25(OH)2D (e.g., phenytoin, phenobarbital,
corticosteroids)
• Chronic kidney disease
• Liver dysfunction
• Obesity
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Recently, vitamin D insufficiency has been
associated with several chronic medical condi-
tions such as osteoporosis, cancers, autoimmune
diseases, and cardiovascular disease. The high
prevalence of vitamin D deficiency combined
with its potential to exacerbate disease have led
to increased exploration of this relationship,
particularly in the field of cardiovascular
medicine. Thus, we conducted a MEDLINE
search of the English-language literature
(1950–2008) to identify studies that examined
this relationship; additional citations were
obtained from the articles retrieved from the
literature search.
Pathophysiology of Vitamin D Deficiency in
Cardiovascular Disease
The first studies to demonstrate a connection
between cardiovascular homeostasis and vitamin
D status used a rat model of vitamin D deficiency
more than 20 years ago.12–14 These animal
studies established a connection between vitamin
D deficiency and cardiovascular dysfunction,
including cardiac hypertrophy, fibrosis,
hypertension, as well as alterations of serum
calcium, parathyroid hormone, and renin levels.
The studies supported a role for vitamin D in
maintaining cardiovascular homeostasis through
both a direct action of 1,25(OH)2D on cardio-
myocyte’s vitamin D receptor and indirect actions
on circulating hormones and calcium.
The first evidence that vitamin D deficiency
could lead to human cardiovascular disease came
from patients with end-stage renal disease
(ESRD). The damaged kidney fails to convert
25(OH)D to 1,25(OH)2D, resulting in a severe
deficiency. In the absence of adequate
1,25(OH)2D levels, secondary hyperpara-
thyroidism develops resulting in elevated levels
of circulating parathyroid hormone.15 Elevated
levels of parathyroid hormone have been
associated with increases in blood pressure and
acute increases in cardiac contractility. The
sustained stress on myocardial tissue leads to
cardiac hypertrophy, myocardial fibrosis, and
heart failure (Figure 2).16 Administration of
activated forms of vitamin D (1,25[OH]2D or
analogs) to patients with ESRD and secondary
hyperparathyroidism has resulted in decreased
left ventricular hypertrophy,17 along with a
decrease in cardiovascular mortality.18, 19 Since
elevations in parathyroid hormone levels are
thought to be a primary cause of cardiac
dysfunction, therapies aimed at decreasing
circulating parathyroid hormone concentrations
are often used in this patient population.
Improvement in blood pressure and left
ventricular hypertrophy regression after
parathyroidectomy in patients with ESRD has
been observed in some, but not all studies.17, 20, 21
The lack of consistent cardiovascular benefit
observed after parathyroidectomy raises the
following question: are long-term elevated levels
of parathyroid hormone the sole cause of cardiac
dysfunction seen in patients with ESRD? Based
on these observations, it has been hypothesized
that vitamin D metabolites not only regulate
parathyroid hormone secretion, but also may
have direct effects on cardiac function.
The vitamin D receptor is widely distributed
throughout the body in several tissue types not
involved in calcium metabolism such as
lymphocytes, colonic cells, hepatocytes, and
cardiac myocytes.22 The extensive expression of
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Table 1. Relationship Between Serum 25-Hydroxyvitamin D Concentration and Health2, 6, 7
25-Hydroxyvitamin D
Concentration
(ng/ml) Status Health Consequence
< 15 Severe deficiency Can lead to rickets and severe bone disease
< 20 Deficient Inadequate bone health and osteoporosis
20–30 Relative insufficiency Recently considered inadequate for optimal health status
> 30 Adequate stores Optimal health status
> 150 Toxicity Hypercalcemia, hyperphosphatemia, and renal impairment
Figure 2. Cardiovascular pathophysiology of vitamin D
deficiency. RAAS = renin-angiotensin-aldosterone system.
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this receptor supports the notion that vitamin D
plays a role in the endocrine system beyond the
regulation of calcium homeostasis.4 Through
interaction with the vitamin D receptor on the
cardiac myocyte, 1,25(OH)2D regulates calcium
influx into the cell, controls the amount of free
cytosolic calcium available thus modifying
contractility of the heart, and controls cell
growth and proliferation.12–14, 23, 24 The direct
physiologic consequences of the absence of the
vitamin D receptor on cardiac function have been
evaluated in several animal studies.25–27 In these
studies, vitamin D receptor knockout mice were
compared with their wild-type littermates at 12
months of life.25, 26 Histologic staining of cardiac
tissue showed highly significant cellular
hypertrophy in the vitamin D receptor knockout
mice, and the heart:body weight ratio was
significantly larger in vitamin D receptor
knockout mice compared with that in wild-type
mice. In addition to cardiac hypertrophy, cardiac
fibrosis and collagen deposition were observed
exclusively in the vitamin D receptor knockout
mice.25, 26 Overall, these findings suggest an
important role for the vitamin D receptor in
cardiac physiology (Figure 2).
The vitamin D receptor knockout mouse has
also provided evidence that vitamin D indirectly
affects cardiac functioning because of its role as a
negative regulator of the renin-angiotensin-
aldosterone system (RAAS)27, 28 (Figure 2). One
group of authors found that vitamin D receptor
knockout mice had more than a 3-fold increase
in renin messenger RNA (mRNA) expression and
more than a 2.5-fold increase in plasma
angiotension II levels compared with wild-type
mice.28 Since 1,25(OH)2D regulates parathyroid
hormone secretion and maintains calcium
homeostatsis, secondary hyperparathyroidism
and hypocalcemia inevitably develop in vitamin
D receptor knockout mice. The vitamin D
receptor knockout mice in their study were
evaluated early in life, before development of
secondary hyperparathyroidism, and were
supplemented with exogenous calcium to
maintain adequate serum levels. Despite normal
serum calcium and parathyroid hormone levels,
vitamin D receptor knockout mice continued to
produce elevated renin mRNA and plasma
angiotensin II levels, suggesting that 1,25(OH)2D
has a direct effect on the RAAS that is
independent of calcium or parathyroid hormone.
In addition to RAAS activation, the upregu-
lation of the immune system is often implicated
in the pathophysiology of cardiovascular disease
(Figure 2). Immune system activation has been
associated with atherosclerotic and valvular
calcification, and plays a role in plaque instability
and rupture.29 Overproduction of inflammatory
cytokines contributes to the development and
progression of heart failure.30 Experimental
studies have suggested that vitamin D plays a role
in the regulation of several important inflam-
matory and antiinflammatory cytokines.31–33 In
one study, a downregulation of inflammatory
cytokine (interleukin [IL]-6 and tumor necrosis
factor [TNF]-) production was observed when
activated monocytes were exposed to
1,25(OH)2D.32 Conversely, in another study, the
production of the antiinflammatory cytokine IL-
10 significantly increased when dendritic cells
were exposed to 1,25(OH)2D compared with
control cells not so exposed.31 The aggregate
data from these investigational studies suggest
that the hormonal form of vitamin D plays an
active and direct role in the regulation of several
immunomodulatory cytokines, resulting in an
overall downregulation of inflammation.
Vitamin D and Hypertension
The data from these experimental laboratory
studies, particularly the association of vitamin D
deficiency with RAAS activation, led to several
small studies that attempted to correlate vitamin
D levels with blood pressure in humans.34–36 In a
small study conducted in 25 patients with
hypertension, the authors found a significant
inverse correlation between 25(OH)D levels and
systolic blood pressure, diastolic blood pressure,
and calf vascular resistance, and a significant
positive correlation between 25(OH)D levels and
calf blood flow.34 A weaker, but still significant,
inverse correlation was also noted between
1,25(OH)2D and systolic and diastolic blood
pressure. Another study conducted in 100
normotensive men found a significant inverse
correlation between serum levels of 1,25(OH)2D
and systolic blood pressure; however, no
significant correlation was noted between
1,25(OH)2D and diastolic blood pressure.35 A
third study did not detect any significant
difference in 25(OH)D levels when comparing
hypertensive patients with matched controls.36
In this study, hypertension was diagnosed based
on one blood pressure reading, raising the
possibility that several normotensive patients
could have been placed in the hypertensive
group.
Subsequently, large cross-sectional studies were
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conducted to confirm these findings.37, 38 The
third National Health and Nutrition Examination
Survey (NHANES III) was a cross-sectional
national survey representative of the noninstitu-
tionalized U.S. population from 1988–1994. One
group of authors analyzed survey participants in
an attempt to define the correlation between
blood pressure and vitamin D status.37 Partici-
pants answered health information question-
naires and reported to mobile examination
centers for blood pressure readings and blood
sampling for determination of 25(OH)D level. A
total of 12,644 patients were included in the
analysis. Although all measurements were based
on a single blood pressure reading, mean blood
pressure varied inversely with serum 25(OH)D
levels, and the association remained significant
even after adjustment for age, sex, race-ethnicity,
and physical activity. Conversely, a smaller cross-
sectional survey conducted in Amsterdam that
included 1205 patients failed to show an
association between blood pressure and serum
25(OH)D levels.38 Methods were similar to those
used in the NHANES III analysis; however,
patients treated with antihypertensive drugs were
not excluded from the analysis. The lack of
association between vitamin D levels and
hypertension may be because only 10% of
patients had vitamin D deficiency compared with
over 20% of patients in the NHANES III analysis.
The authors hypothesized that significant effects
on blood pressure may be seen only in patients
with lower levels of circulating vitamin D.
Among these five initial studies, an association
between hypertension and vitamin D deficiency
was observed in three studies, whereas no
association was observed in two studies.
Although the data from these observational
studies are conflicting, the largest study (>
12,000 patients) did show a statistically
significant association.37
In addition to studying the association between
hypertension and vitamin D deficiency, the risk
of developing hypertension in patients with
vitamin D deficiency was also studied in two
prospective cohort studies that included more
than 1800 patients.39 In men from the Health
Professionals’ Follow-Up Study (HPFS) and
women from the Nurses’ Health Study (NHS I)
without hypertension, the 25(OH)D level was
measured during the study period. Participants
were then followed for 4 years and evaluated for
the development of hypertension. Individuals in
each prospective cohort, evaluated separately or
pooled together, had a greater risk of developing
hypertension if their 25(OH)D level was less than
15 ng/ml compared with those participants
whose 25(OH)D level was greater than 30 ng/ml.
The associations seen between vitamin D
deficiency and hypertension led to two prospec-
tive, randomized, controlled trials studying the
effects of vitamin D supplementation on blood
pressure.40, 41 In one of these studies, women
older than 70 years who had 25(OH)D levels less
than 20 ng/ml were randomly assigned to receive
supplementation with calcium 1200 mg/day only
or calcium 1200 mg/day plus vitamin D
(cholecalciferol) 800 IU/day.41 Compared with
calcium alone, treatment with cholecalciferol led
to a significant reduction in systolic blood
pressure and heart rate. Changes in diastolic
blood pressure did not significantly differ
between the groups. The reduction in systolic
blood pressure was statistically significant
(p=0.02) and appeared clinically significant as
well, with mean ± SD baseline systolic blood
pressure of 144.1 ± 20.4 mm Hg declining to
131.0 ± 16.9 mm Hg after 8 weeks of treatment
with vitamin D.
The other randomized trial was conducted in
34 patients with diabetes mellitus with a serum
25(OH)D level less than 20 ng/ml.40 Patients
were randomly assigned to receive a one-time
dose of ergocalciferol 100,000 IU or placebo.
The primary outcome of endothelial function
assessed by flow-mediated vasodilation of the
brachial artery in response to hyperemia was
significantly improved in vitamin D–treated
patients compared with the placebo group. In
addition, vitamin D supplementation produced a
significant decrease in systolic blood pressure
that was not observed in the placebo group. Both
randomized controlled trials achieved a
significant reduction in systolic blood pressure
with vitamin D supplementation even though the
formulations and dosing regimens of vitamin D
differed greatly between these two studies.
However, each study was only conducted for 8
weeks, so it is unclear if the antihypertensive
effect of vitamin D would be sustained over a
longer period of time.
Table 2 summarizes the results of observational
and randomized studies that evaluated the
relationship between vitamin D and blood
pressure.34–41
Vitamin D and Vascular Disease
Since the activation of the RAAS and the
immune system have been linked to vascular
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disease, exploration of the relationship of vitamin
D deficiency in humans to vascular disease was a
logical next step. Subsequently, vitamin D
deficiency was implicated in several types of
vascular disease including peripheral artery
disease (PAD), atherosclerosis, myocardial
infarction, and ischemic stroke. A recent
NHANES conducted from 2001–2004 was
analyzed to determine the association between
25(OH)D levels and the prevalence of PAD.42 In
this study, PAD was defined as an ankle brachial
index of less than 0.9 and was seen in 406 of the
4839 patients evaluated. Patients with PAD had
significantly lower mean serum 25(OH)D levels
than participants without PAD, although the
difference was numerically small and some may
question its clinical significance. However,
further analysis revealed a graded association
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Table 2. Studies of Vitamin D and Hypertension
25(OH)D Level
Study Population (ng/ml)a Primary Outcome Results
Observational studies
Patients with HTN 17.8 ± 0.2 Correlate 25(OH)D levels Significant inverse correlation was
(n=25)34 with BP noted between 25(OH)D level
and SBP and DBP
Healthy men with 25.3 ± 8.0 Correlate 1,25(OH)2D levels Significant inverse correlation was
no chronic diseases with BP noted between 1,25(OH)2D
(n=100)35 level and SBP; no significant
correlation was noted with DBP
Patients with HTN (n=186) 26 ± 8 (HTN) To compare mean vitamin D No significant difference in
and matched controls 27 ± 11 (no HTN) levels between patients with vitamin D levels between patients
without HTN (n=186)36 and those without HTN with and those without HTN
Patients from NHANES III 31.2 (males) To compare BP between the SBP and DBP were significantly
cohort 29.2 (females) highest quintile (≥ 34 ng/ml) higher in the lowest quintile
(n=12,644)37 and lowest quintile (≤ 16.2 compared with the highest
ng/ml) of serum 25(OH)D quintile
concentrations
Patients from the 21.6 Use multiple linear regression No significant association was
Longitudinal Aging Study to determine the association noted between serum 25(OH)D
(cross-sectional study) between 25(OH)D levels and level and either SBP or DBP
(n=1205)38 SBP or DBP
Patients from the NHS I Not reported To determine the RR of Increased risk of developing HTN
and HPFS prospective developing HTN in those over 4 yrs in both cohorts
cohorts with vitamin D deficiency individually or combined when
(n=1811)39 (< 15 ng/ml) compared with 25(OH)D level was < 15 ng/ml
those with sufficient
vitamin D stores (≥ 30 ng/ml)
Randomized studies
148 women aged ≥ 70 yrs Baseline: To compare SBP, DBP, and Mean SBP and HR were
with serum 25(OH)D 10.3 ± 5.4 (calcium HR between patients who significantly reduced in the
levels < 20 ng/ml + vitamin D) vs received calcium + vitamin D calcium + vitamin D group
(74 received calcium 9.8 ± 4.8 (calcium and those who received compared with the calcium
1200 mg/day + vitamin D alone), p=NS calcium alone alone group
[cholecalciferol]
800 IU/day and 74
received calcium alone)41
34 patients with diabetes Baseline: To compare FMD of the Patients who received
and serum 25(OH)D 16.1 ± 4.1 (vitamin D) brachial artery in response vitamin D had significant
levels < 20 ng/ml vs 14.6 ± 3.4 (placebo), to hyperemia in patients improvement in FMD and
(17 received vitamin D p=0.25 who received vitamin D significantly decreased SBP
[ergocalciferol 100,000 IU with those who received compared with placebo-treated
x 1 dose] and 17 received placebo patients
placebo)40
25(OH)D = 25-hydroxyvitamin D; HTN = hypertension; BP = blood pressure; SBP = systolic blood pressure; DBP = diastolic blood pressure;
1,25(OH)2D = 1,25-dihydroxyvitamin D; NHANES = National Health and Nutrition Examination Survey; NHS = Nurses’ Health Study; HPFS =
Health Professionals’ Follow-Up Study; RR = relative risk; CI = confidence interval; NS = not significant; HR = heart rate; FMD = flow-mediated
vasodilation.
aData are mean or mean ± SD.
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between lower 25(OH)D levels and a higher
prevalence of PAD, suggesting that small
differences in serum 25(OH)D level can greatly
affect PAD risk. The relationship remained
significant even after multivariable adjustment
for age, sex, diabetes, cholesterol levels, statin
use, blood pressure, and chronic kidney disease.42
More severe atherosclerosis, measured by carotid
artery intimal medial thickness, was associated
with lower vitamin D levels in a study conducted
in 390 patients with diabetes.43 Patients with
vitamin D deficiency had significantly greater
carotid artery intimal medial thickness than those
with sufficient vitamin D stores. This relation-
ship remained significant after adjustment for
age, sex, duration of diabetes, low-density
lipoprotein cholesterol (LDL) concentration,
drug therapy, and renal function. The authors
also noted that patients with diabetes had
significantly lower mean 25(OH)D levels
compared with those of age-matched controls
without diabetes. However, it was unclear if the
vitamin D levels in the matched controls were
obtained during the same season as those in the
patients with diabetes.
A clear association between vitamin D status
and the occurrence of acute myocardial infarction
has not been rigorously established. One author
actually found that patients who experienced an
acute myocardial infarction reported a higher
intake of vitamin D (dietary and supplemen-
tation) compared with matched controls.44 This
study did not, however, report serum vitamin D
levels, so the true vitamin D status of these
patients could not be assessed. Based on the
concern that a higher vitamin D status could lead
to an increased frequency of acute myocardial
infarction, several subsequent small studies
attempted to clarify these results.45–47 One study
compared 25(OH)D levels between 15 patients
with a diagnosis of acute myocardial infarction
and 60 aged-matched control patients; vitamin D
levels did not differ significantly between
groups.46 In a study that compared 128 patients
with either acute myocardial infarction or angina
with 409 healthy control subjects, overall
25(OH)D levels were similar between groups.45
However, 25(OH)D levels were significantly
lower in the patients with heart disease compared
with those in the controls in the spring and
summer months.
Another group conducted the first prospective
case-control study of vitamin D levels and the
occurrence of acute myocardial infarction.47
Participants in the Tromso Heart Study who were
free of cardiovascular disease at the outset of the
study were included. They were followed for 4
years, and the primary outcome of acute
myocardial infarction occurred in 30 patients.
Sixty controls matched for age and season of
vitamin D level collection were compared with
the 30 patients who experienced an acute
myocardial infarction. No significant difference
in mean 25(OH)D levels was noted between
groups.
These older studies show no clear association
between vitamin D levels and myocardial
infarction, but they fail to account for LDL
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Table 2. (continued)
Statistical Significance
25(OH)D level and SBP: r = -0.511, p=0.01
25(OH)D level and DBP: r = -0.445, p=0.03
1,25(OH)2D level and SBP: r = -0.24, p=0.016
1,25(OH)2D level and DBP: r = -0.19, p=0.06
p=0.20
p<0.05 for SBP and DBP
p<0.05 after adjustment for age, sex, race-ethnicity, and
physical activity
p=0.64 for SBP
p=0.22 for DBP
p>0.05 after adjustment for multiple confounders
NHS I: RR 2.67 (95% CI 1.05–6.79)
HPFS: RR 6.13 (95% CI 1.00–37.8)
Pooled analysis: RR 3.18 (95% CI 1.39–7.29)
Change in SBP: p=0.02
Change in DBP: p=0.10
Change in HR: p=0.02
FMD: 2.35% vs 0.06%, p=0.048
Change in SBP: -7.3 vs + 6.6 mm Hg, p=0.001
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concentrations, presence of diabetes, or previous
cardiovascular disease—markers we now know
are risk factors for development of a myocardial
infarction.
Almost 30 years after the Tromso Heart Study,
another group published the largest study to date
attempting to define the relationship of vitamin
D levels to the risk of acute myocardial
infarction.48 Men from the HPFS who provided a
blood sample from 1993–1995 were evaluated.
After exclusion of participants with a history of
cardiovascular disease before 1994, 454 men
experienced a nonfatal acute myocardial
infarction or fatal coronary heart disease by 2004.
Nine hundred matched controls without
cardiovascular disease were randomly selected
from study participants and were compared with
the 454 participants who experienced an event.
Plasma 25(OH)D levels were significantly lower
in cases compared with controls, and men with
deficient levels of 25(OH)D had a significantly
elevated risk for acute myocardial infarction.
This relative risk remained significant after
adjustment for family history, diabetes,
hypertension, race-ethnicity, body mass index,
cholesterol levels, and renal function. Vitamin D
deficiency emerged as an independent risk factor
for nonfatal acute myocardial infarction or fatal
coronary heart disease, and men with vitamin D
levels of 30 ng/ml or higher had approximately
half the risk, independent of other factors.
The association of vitamin D deficiency with all-
type cardiovascular disease (defined as coronary
artery disease, PAD, and cerebrovascular disease)
has also been evaluated in several studies.49, 50
More than 400 patients with diabetes without
renal or hepatic disease were evaluated in one
study.49 Serum 25(OH)D concentrations were
measured at a single outpatient visit for all eligible
patients. Patients with vitamin D deficiency
(defined as < 20 ng/ml) had a higher prevalence of
cardiovascular disease. Logistic regression analysis
revealed that the association between vitamin D
deficiency and cardiovascular disease remained
statistically significant after adjustment for renal
function, drug therapy, LDL concentrations,
presence of metabolic syndrome, and hemoglobin
A1c concentrations.
In another study, 1739 participants from the
Framingham Offspring cohort were prospectively
evaluated to determine if lower vitamin D
concentrations could predict the development of
cardiovascular disease.50 To be included in the
analysis, participants had to have serum 25(OH)D
levels measured between 1996 and 2001, and
those with known cardiovascular or kidney
disease were excluded from the analysis.
Participants were then followed for a median of
5.4 years after blood sample collection to
determine the frequency of myocardial infarction,
stroke, angina, transient ischemic attack,
peripheral claudication, or heart failure.
Multivariable Cox regression analysis revealed that
vitamin D deficiency (< 15 ng/ml) was associated
with an increased risk of cardiovascular events.
This association retained statistical significance
after adjustment for renal function, drug therapy,
blood pressure, LDL concentrations, and other
known cardiovascular risk factors. The 5-year rate
of developing a cardiovascular event was twice as
high in those with vitamin D deficiency as in those
with greater vitamin D stores.
Vitamin D deficiency has not only been linked
to several vascular diseases, but has also been
associated with an increase in all-cause and
cardiovascular mortality. The Ludwigshafen Risk
and Cardiovascular Health (LURIC) cohort was
evaluated to determine the relationship between
vitamin D deficiency and mortality.51 Patients
who were referred for coronary angiography were
included in this prospective cohort study. Serum
concentrations of 25(OH)D were measured at
enrollment, and patients were then followed for a
median of 7.7 years. Lower 25(OH)D and
1,25(OH)2D levels were associated with a
statistically significant increase in all-cause and
cardiovascular mortality even after adjustment
for multiple traditional cardiovascular risk
factors. This inverse association with mortality
was noted even in patients who had less than
20% stenosis on baseline angiogram. The
authors concluded that a low 25(OH)D level can
be considered a strong risk indicator for
mortality.
These observational studies have shown a
strong link between vitamin D deficiency and
several types of vascular diseases, including
PAD,42 increased carotid artery intimal medial
thickness,43 and myocardial infarction.48 In
addition, vitamin D deficiency has been
associated with cardiovascular and all-cause
mortality.51–53 Although these studies are
primarily observational, their data support the
hypotheses suggested by early experimental
studies and provide evidence to conduct
prospective randomized trials evaluating the role
of vitamin D supplementation on preventing or
treating vascular disease.
Only one study has evaluated the effect of
vitamin D supplementation on cardiovascular
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disease prevention.54 In the Women’s Health
Initiative, more than 36,000 postmenopausal
women were randomly assigned to receive
calcium 500 mg plus vitamin D3 (cholecalciferol)
200 IU twice/day or matching placebo. Patients
were followed for a mean of 7.0 years, and the
occurrence of cardiovascular events and death
was determined for all patients. Occurrences of
myocardial infarction, stroke, transient ischemic
attack, confirmed angina, coronary artery bypass
grafting or percutaneous coronary intervention,
and cardiovascular death were similar between
the two groups. The authors concluded that
calcium plus vitamin D supplementation does
not decrease the risk for coronary heart disease
or stroke in postmenopausal women. This study,
however, had several limitations that may have
affected the results. Participants assigned to the
calcium plus vitamin D group received a daily
dose of only 400 IU of vitamin D, which may not
be adequate for the prevention of cardiovascular
diseases and is well below the recommended
daily intake of 800 IU for postmenopausal
women for the prevention of osteoporosis.2, 55
Women in the placebo group were permitted to
take vitamin D supplements, which may have
resulted in similar vitamin D intake in each
group, nullifying the differences that might have
been seen between the two groups. Finally,
baseline 25(OH)D levels were not measured in
this study. The benefit of supplementing only
deficient individuals could not be assessed since
treatment assignment was determined irrespec-
tive of vitamin D status. Large prospective trials
assessing adequate doses of vitamin D supple-
mentation in individuals with relatively low
levels are needed to understand the role of
vitamin D in the prevention of cardiovascular
disease.
Table 3 summarizes the results of the
observational and randomized studies that
evaluated the relationship between vitamin D and
vascular disease.42–51, 54
Vitamin D and Heart Failure
The activation of the RAAS and the immune
system associated with vitamin D deficiency has
the potential to cause deleterious effects in
patients with heart failure. The relationship
between vitamin D levels and the frequency and
severity of heart failure has been explored in
several studies.56–62 The authors of one study
measured 25(OH)D levels in 25 African-
American patients with heart failure.58 They
divided patients into three groups: those with
decompensated heart failure for 4 weeks or
longer, those with decompensated heart failure
for 1–2 weeks, and those with compensated heart
failure. Mean 25(OH)D levels were compared
among the groups. Although a trend toward
lower 25(OH)D levels was noted in the most
severely decompensated group, it did not reach
statistical significance. A slightly larger study
conducted with a similar methodology found that
although mean 25(OH)D levels were similar
among the three groups of patients with heart
failure, they were significantly lower than the
mean level of matched controls without heart
failure.57 The average creatinine clearance did
not differ significantly between patients with
heart failure and controls, and blood samples
were obtained during the same season for
patients with heart failure and controls.
Another group of authors enrolled 60 patients
with systolic heart failure and found a significant
positive correlation between 25(OH)D level and
6-minute walk test performance.56 After
multivariable logistic regression, lower vitamin D
levels emerged as an independent predictor of
poorer performance on the 6-minute walk test.
Another study was conducted in 101 patients
with heart failure who were undergoing
evaluation for cardiac transplantation.59 Among
patients on the cardiac transplantation waiting
list, those with more severe heart failure (those
listed as United Network for Organ Sharing
[UNOS] status 1) had significantly lower serum
25(OH)D concentrations than patients who were
less ill (UNOS status 2). In addition, almost 25%
of status 1 patients had severe vitamin D
deficiency compared with less than 10% of status
2 patients.
In another study, 54 patients with New York
Heart Association (NYHA) class II or greater
heart failure with serum creatinine level less than
2 mg/dl were evaluated.60 Twenty patients were
younger than 50 years, and 34 were older than 50
years. A total of 34 elderly matched controls
without heart failure were also evaluated. Serum
25(OH)D concentrations were significantly lower
in patients with heart failure, regardless of age,
compared with the elderly healthy controls. The
authors also noted that elderly patients with
heart failure had significantly higher levels of
TNF- compared with elderly controls. Most
recently, 383 patients with end-stage heart failure
awaiting cardiac transplantation were evaluated
by the same authors.61 Patients were divided into
two groups: those who were designated as an
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Table 3. Studies of Vitamin D and Vascular Disease
Disease State, 25(OH)D Level
Study Population (ng/ml)a Primary Outcome Results
Observational studies
PAD 21.5 ± 0.6 To compare mean 25(OH)D Patients with PAD had significantly lower
Patients from NHANES (PAD) levels between those with and 25(OH)D levels
2001–2004 cohort 24.6 ± 0.5 those without PAD Lowest quintile of 25(OH)D (< 17.8 ng/ml)
(n=4839)42 (no PAD) had a higher prevalence of PAD
compared with the highest quintile of
25(OH)D (≥ 29.2 ng/ml)
Atherosclerosis 19.3 To compare carotid intimal Significantly larger carotid intimal medial
Patients with type 2 medial thickness between thickness in patients with vitamin D
diabetes without patients with vitamin D deficiency compared with those
chronic liver or deficiency and those with without vitamin D deficiency
kidney disease sufficient vitamin D stores
(n=390)43
MI Not measured To compare the average daily Significantly higher average daily intake
150 patients who had an intake of vitamin D among of vitamin D in previous MI group than
MI, 88 with angina, and patients who had a previous in those without a previous MI
and 238 matched MI with those who did not No significant differences were noted
controls44 have a previous MI between angina group and matched
controls
MI 12.8 (MI) To compare 25(OH)D levels No significant differences in 25(OH)D
15 patients who had an 16.8 (controls between patients who had an levels were noted between groups
MI, 60 matched aged 40–60 yrs) MI and matched controls
controls46 8.4 (controls
aged 60–80 yrs)
MI 23.5 ± 10 (MI) To compare 25(OH)D levels 25(OH)D levels were significantly lower
128 patients with chest 23.5 ± 9.6 between patients with chest in patients with chest pain in the spring
pain (53 had an MI, (angina) pain and healthy controls in and summer and not significantly
75 had angina), and 28.8 ± 12.3 each of the four seasons different in fall and winter; overall, no
409 healthy controls45 (controls) significant differences were noted
between groups
MI 23.6 (MI) To compare the mean No significant difference in 25(OH)D
90 patients from the 25.4 (controls) 25(OH)D level between level noted between groups over 4 yrs
Tromso Heart Study participants who had an MI of follow-up
prospective cohort and those who did not
(30 who had an MI,
60 matched controls
who did not)47
MI 22.9 (MI) To compare the mean 25(OH)D Significantly lower 25(OH)D levels were
1354 men from the 24.5 (controls) level between participants who noted in those who had an MI compared
HPFS prospective had an MI and those who did not with those who did not have an MI
cohort (454 who had To determine the RR of having an Men with deficient levels of 25(OH)D
an MI, 900 matched MI in patients with vitamin D had a significantly elevated risk of MI
controls who did not)48 deficiency(< 15 ng/ml) over 10 yrs
All-type CVDb 19.7 To compare the prevalence Prevalence of CVD was greater among
Patients with type 2 of all-type CVD between patients with vitamin D deficiency
diabetes without liver patients with vitamin D Logistic regression revealed a significant
or kidney disease deficiency (< 20 ng/ml) and association between vitamin D
(n=459)49 those without vitamin D deficiency and prevalent CVD
deficiency
All-type CVDb 19.7 To determine the HR of Rate of CVD development was twice as
1739 participants in developing CVD in patients high in those with vitamin D deficiency
the Framingham with vitamin D deficiency as in those without vitamin D deficiency
Offspring prospective (< 15 ng/ml)
cohort (120 developed
CVD, 1619 did not)50
All-type CVDb 17.3 To determine the HR of all-cause All-cause and CV mortality increased
3258 participants in and CV mortality in patients significantly in patients within lowest
the LURIC prospective within the lowest quartile of quartile of vitamin D levels compared
cohort referred for vitamin D levels compared with with those in the highest quartile
coronary angiography51 those in the highest quartile over a median of 7.7 yrs
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elective transplantation listing, and those who
were designated as an urgent transplantation
listing. Serum 1,25(OH)2D concentrations were
determined for all patients at the beginning of the
study, and patients were then followed for 1 year
to assess mortality and need for transplantation.
After multivariable logistic regression, lower
1,25(OH)2D levels were significantly associated
with risk of initial urgent transplantation listing.
In addition, Kaplan-Meier curves illustrated that
a lower 1-year survival rate was noted in those
patients with lower 1,25(OH)2D concentrations.
Finally, the LURIC cohort of patients referred
for coronary angiography, discussed earlier,51 was
subsequently evaluated to determine the
relationship between vitamin D deficiency and
death due to heart failure or sudden cardiac
death.62 This subsequent study evaluated 3299
Caucasian patients from the cohort and followed
them for a median of 7.7 years.62 After adjust-
ment for multiple traditional cardiovascular risk
factors, patients with severe vitamin D deficiency
(25[OH]D < 10 ng/ml) had a significantly
increased risk for death due to heart failure and
sudden cardiac death when compared with
patients with optimal levels of vitamin D
(25[OH]D ≥ 30 ng/ml). In addition, serum
25(OH)D concentrations inversely correlated
with N-terminal pro–B-type natriuretic peptide
(NT-proBNP) levels and NYHA class.
The aggregate data from the above-discussed
seven studies suggest that patients with heart
failure have lower serum vitamin D levels. In the
only randomized trial evaluating vitamin D
supplementation in patients with heart failure, a
total of 123 ambulatory patients with NYHA class
II or greater heart failure were randomly assigned
to receive calcium 500 mg plus cholecalciferol
2000 IU/day or calcium 500 mg plus matching
placebo each day for 9 months.63 Patients with a
serum creatinine level greater than 2 mg/dl were
excluded. Survival rates at 15 months’ follow-up
and changes in biochemical markers at the end of
the 9 months of treatment were compared
between groups. Patients who received vitamin
D supplementation had a significant decrease in
TNF- levels compared with patients receiving
placebo, whose levels actually increased over
time. Conversely, serum levels of the
antiinflammatory cytokine IL-10 significantly
increased in vitamin D–treated patients compared
with patients receiving placebo, whose levels
decreased. No significant differences in left
ventricular ejection fraction (LVEF), C-reactive
protein levels, or blood pressure were noted
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Table 3. (continued)
Statistical Significance
p<0.001, RR 2.18 (95% CI 1.50–3.16)
Differences remained significant after multivariable
adjustment
1.10 ± 0.15 vs 0.87 ± 0.14 mm, p=0.001
Differences in intimal medial thickness remained significant
after multivariable adjustment
MI vs no MI: 31.3 vs 22.9 µg (men), p<0.001; 34.1 vs
20.7 µg (women), p<0.0025
Angina vs controls: p>0.05
p=NS
Patients with chest pain vs healthy controls:
Spring: p<0.01
Summer: p<0.05
Fall: p=NS
Winter: p=NS
All seasons: p=NS
p=NS
p=0.002
RR 2.42 (95% CI 1.53–3.84), p<0.001
RR remained significant after multivariable adjustment
24.4% vs. 35.5%, p=0.01
OR 1.7 (95% CI 1.1–2.6), p<0.01
OR remained significant after multivariable adjustment
HR 2.04 (95% CI 1.42–2.94), p<0.001
HR remained significant after multivariable adjustment
All-cause mortality: HR 3.33 (95% CI 2.66–4.16)
CV mortality: HR 2.22 (95% CI 1.57–3.13)
HR remained significant after multivariable adjustment
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between the two groups. Kaplan-Meier estimates
of survival were not significantly different
between groups. At study completion, vitamin
D–treated patients had a mean 25(OH)D
concentration of 42 ng/ml , which was a
s igni f icant increase from basel ine (14.4
ng/ml), but well below the toxic range (> 150
ng/ml). This study provides the first evidence
that vitamin D supplementation can positively
modify the cytokine profile of patients with heart
failure, which is a research area of great interest.
However, vitamin D supplementation was unable
to improve survival or alternative markers of
heart failure severity such as LVEF, or NT-proBNP
or C-reactive protein levels. The lack of consistent
benefit among all measured variables may relate
to the size of the study population, dose of
vitamin D, or the time between baseline and final
measurements, all of which should be explored
in future studies.
Table 4 summarizes the results of observational
and randomized studies that evaluated the
relationship between vitamin D and heart
failure.56–63
Remaining Controversies for Future Evaluation
In most studies reviewed, a significant inverse
correlation was found between vitamin D
metabolite levels and cardiovascular disease.
This relationship persisted when studied in a
variety of specific cardiovascular disease states
and in both small and large cohorts. However,
most studies merely showed a correlation
between vitamin D deficiency and cardiovascular
disease, without proving causation. It is entirely
possible that patients with cardiovascular
diseases are more debilitated, spend less time in
the sunlight, and consequently have lower
vitamin D levels.
To provide answers to this “chicken or the egg”
debate, prospective trials evaluating the utility of
vitamin D supplementation are necessary. Only a
limited number of prospective, randomized,
controlled trials designed to study the potential
cardiovascular benefit of vitamin D supple-
mentation exist, and analyses were not always
adjusted for renal function, serum vitamin D
levels were not always measured, the seasons in
which vitamin D levels were obtained varied, and
vitamin D intake for patients receiving placebo
was not always controlled. Despite these
limitations, an association between vitamin D
deficiency and cardiovascular disease remains
plausible and warrants further investigation.
Serum Vitamin D Level Threshold
Most studies showed a significant association
between vitamin D deficiency and cardiovascular
disease, but the serum level that defined vitamin
D deficiency differed among studies. Only one
study used an extremely low cutoff, a serum
25(OH)D level below 9 ng/ml, to define vitamin
D deficiency,59 whereas most studies used a level
below 15 ng/ml39, 43, 48, 50 or 20 ng/ml.40, 41, 49 The
two prospective trials showing a benefit with
vitamin D supplementation enrolled patients
only if their 25(OH)D level was less than 20
ng/ml,40, 41 and the third positive prospective
study did not have a cutoff for eligibility, but
mean 25(OH)D serum levels were 14.4 ng/ml
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Table 3. Studies of Vitamin D and Vascular Disease (continued)
Disease State, 25(OH)D Level Statistical
Study Population (ng/ml)a Primary Outcome Results Significance
Randomized study
All-type CVDb Not measured To compare the occurrence Calcium and vitamin D supple- p=NS
36,282 postmenopausal of CVD between patients mentation neither increased nor
women in the WHI who received calcium + decreased the risk for CVD
prospective cohort vitamin D vs those who development over 7 years
(18,176 received calcium received placebo
500 mg + vitamin D
[cholecalciferol]
200 IU twice/day and
18,106 received
matching placebo)54
25(OH)D = 25-hydroxyvitamin D; PAD = peripheral artery disease; NHANES = National Health and Nutrition Examination Survey; MI =
myocardial infarction; NS = not significant; HPFS = Health Professionals’ Follow-Up Study; RR = relative risk; CI = confidence interval; CVD =
cardiovascular disease; OR = odds ratio; HR = hazard ratio; LURIC = Ludwigshafen Risk and Cardiovascular Health cohort; CV =
cardiovascular; WHI = Women’s Health Initiative.
aData are mean or mean ± SD.
bDefined as coronary artery disease, peripheral artery disease, and cerebrovascular disease.
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(range 11.5–22.1 ng/ml) in the vitamin D
treatment group.63 Several large prospective
cohort studies established a lower risk of
developing cardiovascular disease among patients
with serum 25(OH)D levels above 30 ng/ml, a
cutoff that has been suggested to distinguish
vitamin D insufficiency from vitamin D
sufficiency.39, 48, 51 Also, in each randomized
controlled trial, vitamin D–treated patients had
positive clinical outcomes and achieved mean
25(OH)D levels greater than 24 ng/ml and up to
42 ng/ml.40, 41, 63
Based on the variety of cutoff values studied, it
appears that levels less than 15 ng/ml were
generally associated with a higher frequency of
cardiovascular disease, and that risk was seen
with 25(OH)D levels up to 20 ng/ml. Lower
rates of disease were seen mainly in participants
with levels above 30 ng/ml, but benefit, at least in
patients with hypertension, was achieved by
raising serum concentrations above 24 ng/ml.
The cutoff values for vitamin D deficiency and
cardiovascular disease risk suggested by these
studies are in concordance with the latest
definitions of vitamin D deficiency and
insufficiency (Table 1). However, it may not be
biologically reasonable to characterize serum
25(OH)D concentrations as either “deficient” or
“sufficient,” but rather they might represent a
continuous spectrum of cardiovascular disease
risk.
Assessment of Vitamin D Status
What does seem clear from these data is that
25(OH)D concentration is a useful and
appropriate marker of vitamin D status. Most
studies used 25(OH)D exclusively, and those that
also used 1,25(OH)2D generally showed similar,
but often weaker, correlations than were seen
with 25(OH)D.34, 35, 51, 59, 61 Although 1,25(OH)2D
is the biologically active form of vitamin D, it is
not the ideal marker of total body vitamin D
stores. As a person becomes vitamin D deficient
and serum calcium levels decrease, the body
compensates by increasing parathyroid hormone
secretion, which in turn promotes the renal
production of 1,25(OH)2D.7 Thus, despite total
body vitamin D deficiency, 1,25(OH)2D levels
may appear normal. Eventually, the reduced
availability of 25(OH)D will lead to a detectable
decrease in serum 1,25(OH)2D levels, but the
first signs of vitamin D deficiency are best
detected by the serum 25(OH)D level.7 In
addition, although most 25(OH)D is converted to
1,25(OH)2D in the kidney, it is recognized that
many other tissues in the body (brain, colon,
prostate, breast, immune cells, and others) have
the capacity to convert 25(OH)D to 1,25(OH)2D.
These other tissue types rely on this local
production of 1,25(OH)2D to help control cell
growth, differentiation, and activation.6 Therefore,
for the body to maintain physiologic homeostasis,
25(OH)D levels must be adequate, regardless of
1,25(OH)2D concentrations.
Another marker that may be considered for
monitoring vitamin D status is parathyroid
hormone level, since elevated levels are often
implicated in many of these cardiovascular
disease states.16 However, treatment of secondary
hyperparathyroidism in these patients requires
the administration of vitamin D, so evaluating
the vitamin D status of an individual is more
direct, whereas the role of parathyroid hormone
level is confirmatory. Also, some adverse effects
of vitamin D deficiency may occur in the absence
of, or before, the development of secondary hyper-
parathyroidism.28, 61 Most data linking vitamin D
to cardiovascular disease were obtained using
this serum marker, and in the absence of renal
insufficiency, 25(OH)D represents the main
marker of the vitamin D status of an individual.
Vitamin D Supplementation
Along with the uncertainty surrounding serum
vitamin D levels, the preferred formulation and
dosage regimen for vitamin D supplementation
have not been established. Cholecalciferol was
used in two studies,41, 63 whereas ergocalciferol
was used in another.40 Large one-time doses have
been used,40 but smaller daily doses have also
been studied.41, 63 In all of these studies showing
positive clinical outcomes, serum concentrations
of 25(OH)D, calcium, and phosphorus were
measured before and after supplementation.
Although vitamin D supplementation elevated
these serum concentrations from baseline,
elevations above the upper limit of the therapeutic
range were not observed. Daily doses of at least
800 IU and up to 2000 IU appear safe through 15
months of follow-up. The large one-time dose
appeared safe in one particular study,40 but the
timing of when a subsequent dose would be
required was not established. The optimal dose
required to achieve adequate vitamin D stores
likely varies from person to person. Patients
with decreased sun exposure, elevated levels of
cutaneous melanin, or other risk factors for
deficiency will likely require higher doses than
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those in whom these risk factors are absent.
Serum vitamin D level measurements and a risk
factor assessment are needed to individualize
vitamin D supplementation requirements.
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Table 4. Studies of Vitamin D and Heart Failure
25(OH)D Level
Study Population (ng/ml)a Primary Outcome Results
Observational studies
25 African-Americans with HF: 15.1 (DHF ≥ 4 wks) To compare 25(OH)D levels No significant differences in
DHF for ≥ 4 wks in 11, 20.3 (DHF 1–2 wks) among the three HF groups 25(OH)D levels were noted
DHF for 1–2 wks in 9, 23.1 (CHF) among the groups
and 5 patients with CHF58
40 African-Americans with HF 14 ± 1.0 To compare 25(OH)D levels 25(OH)D levels in the three HF
(DHF for ≥ 4 wks in 15, (DHF ≥ 4 wks) among the three HF groups groups were significantly lower
DHF for 1–2 wks in 15, 17 ± 4.0 and control group compared with the control group
and 10 patients with CHF) (DHF 1–2 wks)
and 9 controls without HF57 18 ± 4.0 (CHF)
37.7 ± 7.0 (controls)
Outpatients aged ≥ 60 yrs 26.7 ± 12.5 To correlate 6-min walk Significant positive correlation
with EF < 40% distance with 25(OH)D level was noted between lower
(n=60)56 vitamin D levels and shorter
6-min walk distance
101 patients undergoing 21.0 ± 1.0 To compare 25(OH)D levels Status 1 patients had significantly
cardiac transplantation between UNOS status 1 and lower 25(OH)D and 1,25(OH)2D
evaluation (61 UNOS status 1 status 2 patients levels than status 2 patients;
and 40 UNOS status 2)59 23% of status 1 patients had
severe vitamin D deficiency
(< 9 ng/ml) vs 8% of status 2
patients
54 patients with NYHA class 9.6 (young HF) To compare 25(OH)D levels Patients with HF, regardless of
≥ II HF (20 aged < 50 yrs, 34 11.0 (elderly HF) between younger HF patients age, had significantly lower
aged > 50 yrs) and 34 elderly 18.0 (elderly controls) and elderly controls and 25(OH)D levels than elderly
controls without HF60 between elderly HF patients controls without HF
and elderly controls
383 patients with HF listed 14.0 ± 1.2 To compare 1,25(OH)2D levels Patients in the urgent listing
for cardiac transplantation (elective listing) in those who required urgent group had significantly lower
(325 required elective listing 9.3 ± 0.8 transplantation listing with 1,25(OH)2D levels compared
and 58 required urgent (urgent listing) those who required elective with patients in the elective
listing)61 listing listing group
To examine if 1,25(OH)2D Kaplan-Meier estimates showed
level predicted survival or significantly higher rates of
need for transplantation death or transplantation at
at 1 yr 1 yr in patients with lower
1,25(OH)2D levels
Patients in the LURIC 17.3 To determine the HR for Risk of death due to HF and SCD
prospective cohort referred death due to HF and SCD in was significantly higher in
for coronary angiography patients with vitamin D patients with severe vitamin D
(n=3299)62 deficiency compared with deficiency (< 10 ng/ml) vs those
those with optimal levels of with optimal levels of 25(OH)D
25(OH)D
Randomized study
123 ambulatory patients with Baseline: To determine the survival and Kaplan-Meier estimates showed
NYHA class ≥ II HF and 14.4 (vitamin D) cytokine level differences no significant differences in
Scr < 2 mg/dl (61 received vs 15.3 (placebo), between patients treated with survival rates between groups
calcium 500 mg + vitamin D p=NS vitamin D and those who during the 15-mo follow-up
[cholecalciferol] 2000 IU/day received placebo Statistically significant differences
and 62 received calcium in TNF- and IL-10 level changes
500 mg + matching placebo were noted between groups
each day)63
25(OH)D = 25-hydroxyvitamin D; HF = heart failure; DHF = decompensated heart failure; CHF = compensated heart failure; EF = ejection
fraction; UNOS = United Network for Organ Sharing; LURIC = Ludwigshafen Risk and Cardiovascular Health cohort; NYHA = New York
Heart Association; SCD = sudden cardiac death; TNF- = tumor necrosis factor-; IL = interleukin; Scr = serum creatinine.
aData are mean or mean ± SD.
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Other Considerations
Since most studies found an association
between vitamin D deficiency and cardiovascular
disease risk, some might advocate for widespread
vitamin D supplementation. However, treatment
strategies suggested solely by observational data
may not be effective, and can be harmful. Several
epidemiologic studies have shown an independent
and graded association between cardiovascular
disease risk and elevated homocysteine levels.
Despite this observed correlation, supplementation
with folic acid and B vitamins reduced
homocysteine levels, but did not reduce the risk
of major cardiovascular events.64 Previous
observational studies also suggested that
hormone replacement therapy in postmenopausal
women was associated with a reduction in the
risk of cardiovascular disease. Based on the
Women’s Health Initiative, we now know that,
depending on the age of the patient, estrogen and
progestin replacement using a specific pharma-
ceutical product did not necessarily confer
cardiovascular protection, and may actually
increase risk of coronary heart disease, especially
during the first year of supplementation.65, 66
Finally, dietary and pharmaceutical supplemen-
tation with antioxidants, such as vitamin E and
vitamin C, has been associated with a reduced
risk of coronary disease in epidemiologic and
observational studies. However, supplementation
with these antioxidants in the Women’s Angio-
graphic Vitamin and Estrogen (WAVE) trial67 and
the Heart Protection Study68 resulted in no
benefit.
More than 25 studies have examined the
relationship between vitamin D levels and
cardiovascular disease, and most have shown that
lower vitamin D levels are associated with an
increased risk of cardiovascular disease. None,
however, showed an increased risk of cardio-
vascular disease with higher serum 25(OH)D
levels. This evidence, along with the ability to
measure serum 25(OH)D levels and prevent
hypervitaminosis D, suggests that supplementation
with vitamin D is unlikely to be harmful. In
addition, several studies, not explicitly discussed
in this review, evaluating the safety of vitamin D
supplementation suggest that the tolerable upper
level for vitamin D intake is likely 10–20 times
higher than the current recommended daily
intake.69 From a cardiovascular perspective,
however, because screening for deficiency, using
pharmaceutical supplements, and monitoring for
toxicities all consume health care dollars,
widespread screening and supplementation
should not be advocated until the benefits of
vitamin D supplementation are borne out in large
randomized controlled trials.
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Table 4. (continued)
Statistical Significance
p=NS
p<0.05
r = 0.24, p<0.05
Correlation remained significant after adjustment for age
and sex
25(OH)D level: 19.0 vs 24.0 ng/ml, p≤0.01
1,25(OH)2D level: 23.0 vs 29.0 ng/ml, p≤0.03
Young patients with HF vs control: p<0.001
Elderly patients with HF vs control: p<0.001
1,25(OH)2D level: 17.4 vs 25.5 ng/ml, p<0.001
Survival rates: p<0.001
Kaplan-Meier estimates remained significant after
multivariable adjustment
Death from HF: HR 4.13 (95% CI 1.77–9.62)
SCD: HR 5.98 (95% CI 2.60–13.74)
HR remained significant after multivariable adjustment
Survival rates: 85.7% vs 88.2%, p=0.84
Patients who received vitamin D vs placebo:
Change in TNF- levels: -2.0 vs +2.7, p=0.006
Change in IL-10 levels: +0.24 vs -0.20, p=0.042
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Recommendations for Vitamin D
Supplementation
The strongest recommendation, based on the
available data, is to conduct prospective,
randomized, controlled trials evaluating the
effects of vitamin D supplementation on the
prevention and treatment of various cardio-
vascular diseases. The relevance of the large
body of observational data can only be
determined by the results of well-conducted
prospective trials. Until the results of these
future studies are available, the role of vitamin D
or its metabolites in the management of heart
disease will remain uncertain. Screening and
supplementation should not be considered for
every patient but may be valuable in certain
populations. Patients with several risk factors for
deficiency who have either difficult-to-control
hypertension or heart failure and who have
received maximum medical therapy but remain
symptomatic may reasonably undergo assessment
of their vitamin D status. Patients with serum
25(OH)D concentrations less than 20 ng/ml may
be considered for supplementation.
The known benefits on bone health along with
the relative safety, easy accessibility, and
inexpensive nature of vitamin D supplements
make it a reasonable option for an individual
patient, especially in those for whom traditional
drugs are inadequate. For patients at risk for
osteoporosis, the choice for starting vitamin D
(with calcium) for cardiovascular disease is
perhaps easier. If vitamin D supplementation is
implemented, daily doses of 800–2000 IU can be
considered, with higher doses likely needed in
patients with limited sunlight exposure or other
risk factors for deficiency. As with all other drug
therapies, appropriate monitoring for safety and
efficacy must occur. Although no hypercalcemia,
hyperphosphatemia, or hypervitaminosis D
occurred in these limited number of studies,
monitoring for these toxicities may be necessary,
particularly when higher doses are used. Based
on the half-life of 25(OH)D70 and the follow-up
used in these trials,40, 41, 63 serum calcium,
phosphorus, and 25(OH)D levels could be
measured within 6–15 weeks after initiation of
vitamin D supplementation. Currently, not
enough evidence is available to support long-
term vitamin D supplementation specifically for
the prevention of various cardiovascular diseases.
Conclusion
Experimental animal studies have shown that
vitamin D deficiency leads to increased secretion
of parathyroid hormone and activation of the
RAAS and immune system. A number of
observational studies in humans have also linked
vitamin D deficiency to cardiovascular disease.
Despite this fairly large body of observational
data, very few prospective, randomized,
controlled trials have evaluated the benefit of
vitamin D supplementation on cardiovascular
health. A limited number of studies suggest that
raising 25(OH)D levels may provide benefit to
patients with heart failure or hypertension.
When supplementation is used at studied doses,
it appears safe and well tolerated. Vitamin D
status assessment and supplementation should
not be routine practice but may be considered in
patients not adequately treated despite
optimization of medical therapy. The question of
whether or not vitamin D supplementation can
prevent or treat cardiovascular diseases will be
answered only after the completion of large
randomized controlled trials.
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